000 05065nam a22004455i 4500
999 _c120579
_d120579
_x1
001 120579
003 ES-MaUEC
005 20230102114049.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 200416s2020 gw a o |||| 0|eng d
020 _a9783030410087
024 7 _a10.1007/978-3-030-41008-7
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRM275
_b2020 EB
245 0 0 _aImmunotherapy
_cedited by Aung Naing, Joud Hajjar
250 _a3rd ed. 2020.
264 1 _aCham, Switzerland
_bSpringer International Publishing
_c2020
300 _a1 recurso en línea (XII, 339 páginas)
_b44 ilustraciones, 35 ilustraciones a color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _aArchivo de texto
_bPDF
490 0 _aAdvances in Experimental Medicine and Biology
_x0065-2598
_v1244
490 0 _aBiomedical and Life Sciences (Springer-11642)
505 0 _aOverview of Basic Immunology and Clinical Application -- Advances in Diagnostic Procedures and their Applications in the era of Cancer Immunotherapy -- Immunotherapy for Melanoma -- Immunotherapy in Lung Cancer: From a minor God to the Olympus -- Immunotherapy in Gastrointestinal Malignancies -- Current Landscape of Immunotherapy in Genitourinary Malignancies -- Immuno-oncology for Gynecologic Malignancies -- Immunotherapy for Neuro-Oncology -- Immunotherapy and Radiation -- CAR T-cells -- Skin Reactions to Immune Checkpoint Inhibitors -- Gastrointestinal Tract Adverse Events -- Immune-Related Adverse Events: Pneumonitis -- Hepatobiliary Adverse Events -- Immune Checkpoint Inhibitors (ICIs) Related Cardiotoxicity -- Renal Toxicity -- Immune-Related Oral, Otologic and Ocular Adverse Events -- Cancer Imaging in Immunotherapy -- The Microbiome in Immuno-Oncology -- New developments in the use of Patient-reported outcomes in Cancer Patients undergoing Immunotherapies.
520 3 _aImmunotherapy is a rapidly evolving field that mandates frequent revision of the book as new insights to fight cancer emerge. The third edition of Immunotherapy is an updated overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. It explores the breath of immunotherapeutic strategies available to treat a wide range of cancers, from melanoma and non-small cell lung cancer to gastrointestinal, genitourinary, gynecologic and nervous system malignancies. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the challenges associated with their use undoubtedly increase. As objective response is limited to a subset of patients and is often associated with distinct immune related side effects that are potentially life threatening, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. In the absence of a validated predictive biomarker, innovative technologies and assays are being used to identify critical biomarkers that drive the immune response. Hence, a chapter to provide a basic understanding of the diagnostic procedures has been included besides the chapter on the cellular components of the human immune system. This new edition will also inform readers on use of novel microbiome and imaging approaches. Finally, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies as the authors recognize the importance of including missing patient voice in clinical trials and longitudinal assessment of symptom reports. In short, the third edition of this book provides a comprehensive overview of the latest developments in the field of immune-oncology that will help health care professionals make informed treatment decisions. The book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science.
988 _aSpringer_Biomedlife_23062020
650 7 _aInmunoterapia
_2embne
_9145440
650 7 _aSeroterapia
_2embne
_9675015
700 1 _aNaing, Aung
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_0http://id.loc.gov/authorities/names/n2017186566
_1http://viaf.org/viaf/658150323721009970486
700 1 _aHajjar, Joud
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
_0http://id.loc.gov/authorities/names/n2017186568
_1http://viaf.org/viaf/532150323720209970508
710 2 _aSpringerLink (Online service)
_0http://id.loc.gov/authorities/names/no2005046756
_1http://viaf.org/viaf/148105729
776 0 8 _iPrinted edition:
_z9783030410070
776 0 8 _iPrinted edition:
_z9783030410094
830 0 _aAdvances in Experimental Medicine and Biology,
_x0065-2598 ;
_v1244
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-41008-7
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b07/2020
_dz
_eo
_zSI